216
Participants
Start Date
April 22, 2025
Primary Completion Date
April 2, 2026
Study Completion Date
June 4, 2026
Petrelintide
Petrelintide will be taken by participants once weekly subcutaneously.
Placebo
Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
RECRUITING
Manaasas Clinical Research Center, Manassas
RECRUITING
PharmQuest Life Sciences, LLC, Greensboro
RECRUITING
East Coast Institute for Research - Canton, Canton
RECRUITING
East Coast Institute for Research, LLC, Jacksonville
RECRUITING
Solutions Through Advanced Research, Inc, Jacksonville
RECRUITING
Innovative Research of West Florida, Clearwater
RECRUITING
West Orange Endocrinology P.A, Ocoee
RECRUITING
Cullman Clinical Trials - Family Medicine, Cullman
RECRUITING
AAMRC, Flint
RECRUITING
Iowa Diabetes & Endocrinology Research Center, West Des Moines
RECRUITING
International Diabetes Center, Minneapolis
RECRUITING
Mercury Street Medical Group, PLLC, Butte
RECRUITING
DelRicht Research - New Orleans, New Orleans
RECRUITING
Lynn Institute of Norman, Norman
RECRUITING
Juno Research LLC, Houston
RECRUITING
Consano Clinical Research, Shavano Park
RECRUITING
Elligo Clinical Research, Inc., Austin
RECRUITING
Elite Clinical Studies, LLC, Phoenix
RECRUITING
Palm Research Center, Inc., Las Vegas
RECRUITING
Velocity Clinical Research, Huntington Park
WITHDRAWN
AMCR Institute, Inc., Escondido
RECRUITING
Diablo Clinical Research Inc., Walnut Creek
RECRUITING
Medical Investigation Inc, Little Rock
RECRUITING
Chase Medical Research, LLC, Waterbury
RECRUITING
The University of Texas Southwestern Medical Center, Dallas
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
Zealand Pharma
INDUSTRY